Stockscreener 앱 받기
7.56
1.82%
-0.14
전일 마감가:
$7.70
열려 있는:
$7.9245
하루 거래량:
14,230
Relative Volume:
0.37
시가총액:
$71.23M
수익:
-
순이익/손실:
$-129.41M
주가수익비율:
-0.3138
EPS:
-24.0922
순현금흐름:
$-51.97M
1주 성능:
-4.79%
1개월 성능:
-1.31%
6개월 성능:
+26.42%
1년 성능:
+0.00%
1일 변동 폭
$7.4394
$7.9245
1주일 범위
$7.4394
$8.40
52주 변동 폭
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
명칭
Leonabio Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
7.56 | 72.55M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Leonabio Inc 주식(LONA)의 최신 뉴스
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - Vinanet
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - Vinanet
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio’s lasofoxifene to be featured at breast cancer summit By Investing.com - Investing.com Nigeria
LeonaBio’s lasofoxifene to be featured at breast cancer summit - Investing.com
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer - The Manila Times
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), - GlobeNewswire
LeonaBio Ord Shs (LONA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LONA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares RisePost-Earnings Reaction - vinanet.vn
LONA Q1 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineEPS Growth Report - vinanet.vn
LONA: LeonaBio, Inc.12 Month EPS - Zacks Investment Research
LeonaBio Inc. (LONA) Slips 2.74% to $7.45 as Biotech Stock Nears Key SupportDividend ETF - vinanet.vn
LeonaBio Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-than-Expected Loss Driven by Expense ManagementRevenue Estimate Trend - vinanet.vn
LeonaBio Inc. (LONA) Advances 2.08%: Biotech Stock Tests Mid-Range Resistance After Oversold BounceBreakaway Gap - dars.gov.et
LONA|LeonaBio Ord Shs|Price:7.275|Chg%:-0.115 - TradingKey
LeonaBio Ord Shs (LONA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LeonaBio, Inc. Revenue Breakdown – NASDAQ:LONA - TradingView
LeonaBio Ord Shs (LONA) Institutional Confidence - TradingKey
LONA Q1 2026 Earnings: EPS Surprises to the Upside as Biotech Advances PipelineBook Value Growth - vinanet.vn
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations, Stock Rises 5.7%Consensus Miss Rate - vinanet.vn
LONA Q1 2026 Earnings: EPS Beat Drives 4.85% Stock Surge Despite Zero RevenueNon-GAAP Earnings - Vinanet
LeonaBio Inc. (LONA) Drops 7.55% as Selling Pressure Intensifies, Testing Key SupportMomentum Stock Picks - dars.gov.et
Mizuho Securities Remains a Buy on LeonaBio (LONA) - The Globe and Mail
LONA Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Despite Revenue AbsenceNext Quarter Guidance - vinanet.vn
LeonaBio (LONA) Tumbles 8.4% as Stock Tests Key Support Levels Near $7.42Momentum Breakout Ideas - Vinanet
LONA Q1 2026 Earnings: Beats EPS Estimates Amidst Pre-Revenue StageNet Profit Margin - dars.gov.et
LeonaBio Inc. (LONA) Gains 2.24% as Stock Approaches Key Resistance at $10.08Stop Loss Guidance - dars.gov.et
LONA Q1 2026 Earnings: Narrower-than-expected loss lifts sharesManagement Tone Analysis - dars.gov.et
Form 4 LeonaBio Inc For: 10 July By Investing.com - Investing.com Nigeria
LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role - Stock Titan
Form 4 LeonaBio Inc For: 9 July By Investing.com - Investing.com Nigeria
Leonabio Inc (LONA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Leonabio Inc 주식 (LONA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
0.86%
0.31%
자본화:
|
볼륨(24시간):